207 related articles for article (PubMed ID: 21424129)
1. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells.
Manca A; Sini MC; Izzo F; Ascierto PA; Tatangelo F; Botti G; Gentilcore G; Capone M; Mozzillo N; Rozzo C; Cossu A; Tanda F; Palmieri G
Oncol Rep; 2011 Jun; 25(6):1495-502. PubMed ID: 21424129
[TBL] [Abstract][Full Text] [Related]
2. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo.
Ensor CM; Holtsberg FW; Bomalaski JS; Clark MA
Cancer Res; 2002 Oct; 62(19):5443-50. PubMed ID: 12359751
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic cancer cell lines deficient in argininosuccinate synthetase are sensitive to arginine deprivation by arginine deiminase.
Bowles TL; Kim R; Galante J; Parsons CM; Virudachalam S; Kung HJ; Bold RJ
Int J Cancer; 2008 Oct; 123(8):1950-5. PubMed ID: 18661517
[TBL] [Abstract][Full Text] [Related]
4. The Combination of Arginine Deprivation and 5-Fluorouracil Improves Therapeutic Efficacy in Argininosuccinate Synthetase Negative Hepatocellular Carcinoma.
Thongkum A; Wu C; Li YY; Wangpaichitr M; Navasumrit P; Parnlob V; Sricharunrat T; Bhudhisawasdi V; Ruchirawat M; Savaraj N
Int J Mol Sci; 2017 Jun; 18(6):. PubMed ID: 28587170
[TBL] [Abstract][Full Text] [Related]
5. Recombinant human arginase inhibits proliferation of human hepatocellular carcinoma by inducing cell cycle arrest.
Lam TL; Wong GK; Chong HC; Cheng PN; Choi SC; Chow TL; Kwok SY; Poon RT; Wheatley DN; Lo WH; Leung YC
Cancer Lett; 2009 May; 277(1):91-100. PubMed ID: 19138817
[TBL] [Abstract][Full Text] [Related]
6. Anti-tumor activity of arginine deiminase via arginine deprivation in retinoblastoma.
Kim JH; Kim JH; Yu YS; Kim DH; Min BH; Kim KW
Oncol Rep; 2007 Dec; 18(6):1373-7. PubMed ID: 17982619
[TBL] [Abstract][Full Text] [Related]
7. Arginine deprivation as a targeted therapy for cancer.
Feun L; You M; Wu CJ; Kuo MT; Wangpaichitr M; Spector S; Savaraj N
Curr Pharm Des; 2008; 14(11):1049-57. PubMed ID: 18473854
[TBL] [Abstract][Full Text] [Related]
8. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion.
Cheng PN; Lam TL; Lam WM; Tsui SM; Cheng AW; Lo WH; Leung YC
Cancer Res; 2007 Jan; 67(1):309-17. PubMed ID: 17210712
[TBL] [Abstract][Full Text] [Related]
9. Imaging of tumor vascularization using fluorescence molecular tomography to monitor arginine deiminase treatment in melanoma.
Stelter L; Evans MJ; Jungbluth AA; Longo VA; Zanzonico P; Ritter G; Bomalaski JS; Old L; Larson SM
Mol Imaging; 2013; 12(1):67-73. PubMed ID: 23348793
[TBL] [Abstract][Full Text] [Related]
10. Arginine deprivation as a new treatment strategy for head and neck cancer.
Huang CC; Tsai ST; Kuo CC; Chang JS; Jin YT; Chang JY; Hsiao JR
Oral Oncol; 2012 Dec; 48(12):1227-35. PubMed ID: 22917549
[TBL] [Abstract][Full Text] [Related]
11. Targeting argininosuccinate synthetase negative melanomas using combination of arginine degrading enzyme and cisplatin.
Savaraj N; Wu C; Li YY; Wangpaichitr M; You M; Bomalaski J; He W; Kuo MT; Feun LG
Oncotarget; 2015 Mar; 6(8):6295-309. PubMed ID: 25749046
[TBL] [Abstract][Full Text] [Related]
12. Arginine deiminase PEG20 inhibits growth of small cell lung cancers lacking expression of argininosuccinate synthetase.
Kelly MP; Jungbluth AA; Wu BW; Bomalaski J; Old LJ; Ritter G
Br J Cancer; 2012 Jan; 106(2):324-32. PubMed ID: 22134507
[TBL] [Abstract][Full Text] [Related]
13. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes.
Kuo MT; Savaraj N; Feun LG
Oncotarget; 2010 Aug; 1(4):246-51. PubMed ID: 21152246
[TBL] [Abstract][Full Text] [Related]
14. Arginine Deiminase Enzyme Evolving as a Potential Antitumor Agent.
Somani RR; Chaskar PK
Mini Rev Med Chem; 2018; 18(4):363-368. PubMed ID: 27538511
[TBL] [Abstract][Full Text] [Related]
15. Arginine deiminase as a novel therapy for prostate cancer induces autophagy and caspase-independent apoptosis.
Kim RH; Coates JM; Bowles TL; McNerney GP; Sutcliffe J; Jung JU; Gandour-Edwards R; Chuang FY; Bold RJ; Kung HJ
Cancer Res; 2009 Jan; 69(2):700-8. PubMed ID: 19147587
[TBL] [Abstract][Full Text] [Related]
16. Expression of argininosuccinate synthetase in patients with hepatocellular carcinoma.
Wu L; Li L; Meng S; Qi R; Mao Z; Lin M
J Gastroenterol Hepatol; 2013 Feb; 28(2):365-8. PubMed ID: 23339388
[TBL] [Abstract][Full Text] [Related]
17. Negative argininosuccinate synthetase expression in melanoma tumours may predict clinical benefit from arginine-depleting therapy with pegylated arginine deiminase.
Feun LG; Marini A; Walker G; Elgart G; Moffat F; Rodgers SE; Wu CJ; You M; Wangpaichitr M; Kuo MT; Sisson W; Jungbluth AA; Bomalaski J; Savaraj N
Br J Cancer; 2012 Apr; 106(9):1481-5. PubMed ID: 22472884
[TBL] [Abstract][Full Text] [Related]
18. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase.
Yoon CY; Shim YJ; Kim EH; Lee JH; Won NH; Kim JH; Park IS; Yoon DK; Min BH
Int J Cancer; 2007 Feb; 120(4):897-905. PubMed ID: 17096330
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of argininosuccinate synthetase is associated with cisplatin resistance in hepatocellular carcinoma cell lines: implications for PEGylated arginine deiminase combination therapy.
McAlpine JA; Lu HT; Wu KC; Knowles SK; Thomson JA
BMC Cancer; 2014 Aug; 14():621. PubMed ID: 25164070
[TBL] [Abstract][Full Text] [Related]
20. Recombinant human arginase inhibits the in vitro and in vivo proliferation of human melanoma by inducing cell cycle arrest and apoptosis.
Lam TL; Wong GK; Chow HY; Chong HC; Chow TL; Kwok SY; Cheng PN; Wheatley DN; Lo WH; Leung YC
Pigment Cell Melanoma Res; 2011 Apr; 24(2):366-76. PubMed ID: 21029397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
